| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 62.182 | 18.455 | 55.969 | 38.410 | 17.201 | 9.095 | 2.377 | 0 | 2.146 | 0 |
| Total Income - EUR | 62.813 | 18.455 | 55.969 | 47.739 | 22.919 | 10.087 | 2.377 | 0 | 2.146 | 0 |
| Total Expenses - EUR | 42.451 | 14.524 | 38.281 | 26.711 | 19.070 | 8.799 | 5.285 | 1.171 | 1.658 | 146 |
| Gross Profit/Loss - EUR | 20.362 | 3.931 | 17.688 | 21.028 | 3.849 | 1.288 | -2.908 | -1.171 | 488 | -146 |
| Net Profit/Loss - EUR | 18.477 | 3.378 | 16.516 | 20.550 | 3.620 | 985 | -2.978 | -1.171 | 410 | -146 |
| Employees | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 |
Check the financial reports for the company - Bioline International S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 29.306 | 27.003 | 11.807 | 4.184 | 253 | 248 | 243 | 243 | 243 | 241 |
| Current Assets | 39.858 | 42.075 | 81.467 | 105.764 | 104.270 | 102.180 | 93.130 | 150 | 265 | 117 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 2.469 | 3.744 | 3.675 | 3.689 | 2.742 | 515 | 72 | 82 | 81 |
| Cash | 39.858 | 39.606 | 77.723 | 102.089 | 100.581 | 99.439 | 92.615 | 78 | 183 | 36 |
| Shareholders Funds | 44.884 | 47.804 | 76.774 | 95.916 | 97.678 | 96.811 | 91.687 | -916 | -504 | -647 |
| Social Capital | 236 | 234 | 230 | 226 | 221 | 217 | 212 | 0 | 212 | 211 |
| Debts | 24.280 | 21.274 | 16.500 | 14.032 | 6.845 | 5.617 | 1.686 | 1.309 | 1.011 | 1.005 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4711 - 4711" | |||||||||
| CAEN Financial Year |
4711
|
|||||||||
Comments - Bioline International S.r.l.